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THERAPY: LET THE SCIENCE DECIDE
Sabrina K. Glavota*
Abstract
Mitochondrial replacement therapy (MRT) is an in vitro
fertilization technique designed to prevent women who are carriers of 
mitochondrial diseases from passing on these heritable genetic 
diseases to their children. It is an innovative assisted reproductive 
technology that is only legal in a small number of countries. The 
United States has essentially stagnated all opportunities for research 
and clinical trials on MRT through a rider in H.R.2029 – Consolidated 
Appropriations Act, 2016. The rider bans clinical trials on all 
therapies in which a human embryo is intentionally altered to include 
a heritable genetic modification. This note argues that the rider should 
be amended to permit therapies such as MRT, which do not create 
artificial DNA sequences, while continuing to prohibit clinical trials 
on germline therapies that modify the sequence of a gene. MRT is 
distinct from the types of therapies that Congress intended to ban 
through the rider. Amending the rider would not automatically 
approve MRT trials, but rather allow the FDA to evaluate 
investigational new drug applications and determine whether 
individual trials may proceed. Without proper FDA oversight, carriers 
of mitochondrial diseases are denied access to a therapy that provides 
them with benefits they cannot enjoy by any other means, and 
researchers may look abroad to conduct the therapy illegally or 
dangerously. Further, the United States can look to other countries 
such as the United Kingdom as a model for how to proceed with 
research and trials on MRT in an ethical manner.
* J.D. Candidate, Class of 2022, University of Michigan Law School. I would like to 
thank Professor Rebecca Eisenberg for introducing me to FDA Law, for assistance in the writ-
ing process, and for encouraging me to publish. I would also like to thank the MTLR team for 
their thoughtful edits.
346 Michigan Technology Law Review [Vol. 27:345
Table of Contents
INTRODUCTION...................................................................................... 347
I. Mitochondrial Replacement Therapy .................................. 348
A. Mitochondrial Replacement Therapy: Method and 
Purpose.................................................................................. 349
1. Inheritance of mtDNA Diseases ..................................... 349
2. MRT Can Prevent mtDNA Diseases .............................. 350
3. MRT Trials in Animals Have Been Successful .............. 352
B. Current Treatment Options for Women Who Are Carriers 
of Mitochondrial Diseases..................................................... 354
II. United States Regulation Of Gene, Cell, And Embryo 
Therapies..................................................................................... 354
A. Human Cells, Tissues, and Cellular and Tissue Based 
Products (HCT/Ps) ................................................................ 354
B. The Congressional Ban of MRT............................................. 357
III. Research And Clinical Trials On Mitochondrial 
Replacement Therapy Should Be Allowed in the 
United States ............................................................................ 359
A. MRT is Legal in Other Countries and Has Produced 
Positive Results...................................................................... 360
1. MRT Is Legal in the United Kingdom as a Clinical 
Procedure for Assisted Reproduction ............................. 360
2. Greece and Ukraine Have Had Successful Births 
Through MRT................................................................. 361
3. Other Countries, Including Spain and Singapore, Are 
Considering Legalizing MRT ......................................... 362
B. MRT is Distinct from the Types of Therapies That Have 
Been Met with the Most Vehement Societal Opposition ........ 362
C. Removing the Rider Simply Enables the FDA to Perform 
Its Job and Evaluate Applications for Clinical Trials ........... 364
D. Political and Legislative Resistance is Based on Past 
Therapies that are Unrelated to MRT.................................... 365
1. Issues with Past Unrelated Gene Therapies .................... 366
2. The Fight Over Stem Cell Research ............................... 367
E. Without FDA Regulation and the Opportunity for 
Approval, Researchers and Patients Will Look Abroad or 
Conduct MRT Illegally and Dangerously .............................. 368
F. Ethical Considerations Counsel in Favor of Allowing 
Parents to Choose Whether to Pursue MRT.......................... 369
1. Rights of the Egg Donor ................................................. 369
2. Children Born from MRT ............................................... 370
3. Limits on MRT’s Therapeutic Scope.............................. 372
G. The Health Risks of MRT are Unproven and Can Only be 
Discovered Through Further Research ................................. 373
Spring 2021] Mitochondrial Replacement Therapy 347
H. MRT Provides Benefits Carriers of Mitochondrial 
Diseases ................................................................................. 373
1. MRT Provides Carriers with the Potential to Have a 
Healthy Baby to Whom they are Biologically 
Related ............................................................................ 374




Mitochondrial diseases are inherited from a child’s mother
1
through her 
mitochondrial DNA (mtDNA). Many of these diseases are severe, incurable, 
and can be fatal. Mitochondrial replacement therapy (MRT) is an assisted 
reproductive technology through which a woman who is a carrier for a mi-
tochondrial disease can prevent transmission to her child. Assisted repro-
ductive technologies are fertility treatments intended to result in pregnancy 
that involve manipulating the egg, sperm, or both in vitro.2 These include 
intrauterine insemination and in vitro fertilization (IVF).3 MRT involves al-
terations to the egg or embryo prior to implantation, and this means that it 
falls under the broad class of gene therapies that are considered germline 
therapies.
Currently, clinical trials of MRT cannot proceed in the United States 
because of a ban on germline therapies enacted by Congress in 2016 
through a rider in H.R.2029 – Consolidated Appropriations Act, 2016. This 
note argues that the rider should be modified to specifically ban germline 
therapies that create artificial DNA sequences, but permit MRT, which does 
not edit the sequence of individual genes. Part I describes the technique be-
hind MRT and how it prevents transmission of mitochondrial diseases from 
mother to child. Part II describes the regulatory landscape in the United 
States that covers genetic, cellular, and embryonic therapies. Part III pro-
poses an amendment to the rider which would allow research and clinical 
trials on MRT to progress while addressing and dismantling arguments 
1. For the purposes of this note, “mother” refers to a prospective parent who has an 
egg with mutated mitochondrial DNA and wishes to replace their mutated mtDNA with nor-
mal mtDNA from a donor. The author recognizes that this gendered language does not en-
compass all gender identities of prospective parents who may use this therapy. These terms 
are used throughout because the field lacks gender-neutral alternatives with the same level of 
specificity. The author acknowledges that issue has not been adequately addressed by the 
field.
2. See generally Assisted Reproductive Technology (ART), NAT’L INSTS. OF HEALTH
(Jan. 31, 2017), https://www.nichd.nih.gov/health/topics/infertility/conditioninfo/treatments
/art.
3. Id.
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against the use of MRT. This note concludes by reiterating that in order to 
learn if MRT is a viable therapy, further research must be conducted, and 
these decisions should be left to the scientific regulatory agency: the FDA.
I.  Mitochondrial Replacement Therapy
Every year 1,000 to 4,000 babies born in the United States are affected 
by mitochondrial diseases.
4
Mitochondrial diseases are a result of muta-
tions
5
in mitochondrial DNA (mtDNA).
6
mtDNA is inherited entirely from a 
child’s mother, as an embryo only receives mtDNA from the mother’s egg, 
not the father’s sperm.
7
If the proportion of mutant mtDNA is over a certain 
threshold, usually sixty percent in humans, then the individual develops a 
severe disease such as liver failure, sensory deficit disorder, neuropathy, 
myopathy, or cardiomyopathy.
8
Inherited mitochondrial diseases are not 
curable, and can be fatal.
9
One disease that results from mutated mtDNA is 
Leigh syndrome,
10
“a severe neurological disorder that usually becomes ap-
parent in the first year of life. This condition is characterized by progressive 
loss of mental and movement abilities (psychomotor regression) and typi-
cally results in death within two to three years, usually due to respiratory 
failure.”
11
Another mitochondrial disease is myoclonic epilepsy with rag-
ged-red fibers (MERRF) syndrome.
12
This is a rare syndrome which typical-
ly affects the muscles and nervous system, and causes twitches, weakness 
4. Emily Mullin, Patient Advocates and Scientists Launch Push to Lift Ban on 
“Three-Parent IVF”, STAT (Apr. 16, 2019), https://www.statnews.com/2019/04/16
/mitochondrial-replacement-three-parent-ivf-ban.
5. Most mtDNA mutations are not harmful and have no effect. Everyone carries many 
of these benign mutations in their mtDNA. For the purposes of this note, “mutant” mtDNA 
refers only to those mutations that are harmful, while “normal” mtDNA refers to mtDNA that 
has benign mutations. See generally Jing Wang et al., An Integrated Approach for Classifying 
Mitochondrial DNA Variants: One Clinical Diagnostic Laboratory’s Experience, 14 
GENETICS MED. 620 (2012).
6. See generally Tian Wang et al., Polar Body Genome Transfer for Preventing the 
Transmission of Inherited Mitochondrial Diseases, 157 CELL 1591 (2014).
7. See César Palacios-González, A Third MRT-Baby on Its Way, UNIV. OXFORD:
PRACTICAL ETHICS (Jan. 22, 2019), http://blog.practicalethics.ox.ac.uk/2019/01/a-third-mrt-
baby-is-on-its-way.
8. Wang et al., supra note 6, at 1591.
9. Id.
10. Leigh Disease or Syndrome, UNITED MITOCHONDRIAL DISEASE FOUND.,
https://www.umdf.org/mitochondrial-disease-types/leigh-disease-or-syndrome (last visited 
Apr. 28, 2021).
11. Leigh Syndrome, MEDLINEPLUS (June 1, 2016), https://medlineplus.gov/genetics
/condition/leigh-syndrome/#:~:text=Leigh%20syndrome%20is%20a%20severe,usually%20
due%20to%20respiratory%20failure.
12. Myoclonic Epilepsy with Ragged-Red Fibers, MEDLINEPLUS (May 1, 2014), 
https://medlineplus.gov/genetics/condition/myoclonic-epilepsy-with-ragged-red-fibers.
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and progressive stiffness.
13
The physical presentation of MERRF varies 
widely from one individual to the next.
14
There are over thirty different 
types of mitochondrial diseases of varying severity, presentation and preva-
lence.
15
A. Mitochondrial Replacement Therapy: Method and Purpose
Replacing the mother’s mutant mitochondrial DNA with normal mito-
chondria from a donor egg significantly reduces the risk of a woman passing 
on mutant mtDNA to her child. Animal studies of MRT have demonstrated 
efficacy in preventing inheritance of mtDNA diseases.
16
1. Inheritance of mtDNA Diseases
All humans have two types of DNA: nuclear and mitochondrial.
17
Nu-
clear DNA encodes the vast majority of our traits, while mtDNA codes a 
small number of mitochondrial proteins.
18
mtDNA accounts for less than 





These genes produce proteins which are vital to apoptosis 
(programmed cell death) and which produce energy within the cell.
21
Each 
cell contains one complete set of nuclear DNA but there are multiple copies 
of mtDNA present within the cell.
22
Fertilization is the process by which the male and female sex cells, 
called gametes, combine to form an embryo, also called a zygote.
23
The egg 
is the larger gamete that provides most of the contents of the combined zy-
gote. Mitochondria are present in the cell cytoplasm. The egg, or oocyte, is 
13. Id.
14. Id.
15. Types of Mitochondrial Disease, UNITED MITOCHONDRIAL DISEASE FOUND.,
https://www.umdf.org/what-is-mitochondrial-disease/types-of-mitochondrial-disease (last vis-
ited Apr. 3, 2021).
16. See Masahito Tachibana et al., Mitochondrial Replacement Therapy and Assisted 
Reproductive Technology: A Paradigm Shift Toward Treatment of Genetic Diseases in Gam-
etes or Early Embryos, 17 REPROD. MED. & BIOL. 421, 423, 425–26 (2018).
17. Clinical Investigations of Mitochondrial Replacement Techniques Are ‘Ethically 
Permissible’ if Significant Conditions Are Met, Says New Report, NAT’L ACADS. SCIS.,
ENG’G & MED. (Feb. 3, 2016), https://www.nationalacademies.org/news/2016/02/clinical-
investigations-of-mitochondrial-replacement-techniques-are-ethically-permissible-if-
significant-conditions-are-met-says-new-report [hereinafter NAT’L ACADS. Report].
18. Robert W. Taylor & Doug M. Turnbull, Mitochondrial DNA Mutations in Human 
Disease, 6 NATURE REVS. GENETICS 389, 391 (2005).
19
.
Rosa J. Castro, Mitochondrial Replacement Therapy: The UK and US Regulatory 
Landscapes, 3 J.L. & BIOSCIS. 726, 727 (2016).
20. Tachibana et al., supra note 16, at 422.
21. Id.
22. Taylor & Turnbull, supra note 18, at 389.
23. Katerina Georgadaki et al., The Molecular Basis of Fertilization (Review), 38 INT’L
J. MOL. MED. 979, 979 (2016).
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the gamete that provides all of the cell cytoplasm and organelles to the 
combined zygote once fertilization is complete. There is a significantly 
higher number of mtDNA molecules in an oocyte than in a sperm cell, or 
spermatocyte: a mature oocyte has 200,000 to 300,000 mtDNA copies, 
whereas a spermatocyte has approximately 100 mtDNA copies.
24
Any mito-
chondria present in a zygote that come from the spermatocyte are specifical-
ly eliminated during early embryo development.
25
This means that the 
mother provides all of the mitochondria and mtDNA, and so mitochondrial 
diseases can only be passed down from the mother.
26
Because mtDNA and 
mitochondrial diseases can only be passed on to a child by the mother, 
mtDNA therapies must deal with eggs or embryos at the preimplantation
stage in order to prevent the inheritance of mutant mtDNA.
The severity of a mitochondrial disease is highly dependent on the 
number of mutated mtDNA copies, so the physical manifestation of the dis-
ease varies greatly from one individual to the next.
27
A higher ratio of mu-
tant to normal mtDNA molecules within a person’s cells can cause disease 
presentation to be more severe.
28
Typically, in order for a mtDNA disease to 
manifest in a human, sixty percent or more of the mtDNA must be mutat-
ed.
29
2. MRT Can Prevent mtDNA Diseases
Germline therapy is a type of gene therapy. Gene therapy is a technique 
that can be used to treat a genetically inherited disease or illness.
30
There are 
two types of cells in which gene therapy can be performed: somatic and 
germline. Somatic cells are normal body cells, whereas germline cells are 
sex cells that create offspring. Somatic gene therapy involves changing, fix-
ing, or replacing genes in one individual, whereas germline therapy results 
in genetic changes to the individual on which the therapy is performed as 
well as all of their offspring.
31
Genetic changes made in germline cells are 
passed down to the offspring of that individual because germline cells are 
involved in the creation of the embryos, if that individual chooses to repro-
duce.
24. Tachibana et al., supra note 16, at 422.
25. See, e.g., Peter Sutovsky et al., Ubiquitin Tag for Sperm Mitochondria, 402 
NATURE 317, 371–72 (1999).
26. E.g., Castro, supra note 19, at 727.
27. Taylor & Turnbull, supra note 18, at 391–92.
28. See Tachibana et al., supra note 16, at 422.
29. Id. at 426.
30. What Is Gene Therapy? MEDLINEPLUS (Sept. 21, 2020), https://medlineplus.gov
/genetics/understanding/therapy/genetherapy/#:~:text=Gene%20therapy%20is%20an%20
experimental,of%20using%20drugs%20or%20surgery.
31. Tachibana et al., supra note 16, at 422.
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Mitochondrial Replacement Therapy is an IVF technique that is de-
signed to prevent a mother
32
from passing down mutated mtDNA to a 
child.
33
There are two processes by which MRT can be performed: maternal 
spindle fiber transfer (MST) and pronuclear transfer. Both processes use a 
donor egg who has normal mtDNA.
34
In the first process, maternal spindle transfer, the nucleus is removed 
from the donor egg.
35
The mother’s nuclear DNA, in the form of a spindle-
chromosome complex, is removed from the egg cell in a karyoplast (mem-
brane-enclosed nuclear DNA).
36
The nucleus in the donor egg is replaced 
with the mother’s nuclear DNA.
37
The combined egg is fertilized, and then 
the embryo is implanted into the mother or a surrogate.
38
The second process, pronuclear transfer, is essentially the same as 
MST, but the donor’s egg nucleus is replaced with the mother’s nucleus af-
ter fertilization.
39
In pronuclear transfer, both eggs are fertilized, and then 
the nucleus of the zygote formed with the donor egg is removed and re-
placed with the nucleus from the zygote formed with the mother’s egg.
40
MRT is sometimes called “three-parent IVF” because a child born from this 
technique has inherited genetic material from three people, although the ge-
netic contribution from the donor is small and only present in the mitochon-
dria.
41
The nuclear DNA contains the bulk of human genetic material, which 
means the person providing the nuclear DNA is the biologically related to 
the child.
42
The person who provides the egg is a donor, and that nuclear 
DNA is replaced before implantation, and so the egg donor is not the par-
ent.
43
Since mitochondria are only present in female sex cells, using a donor 
egg with normal mitochondrial DNA (instead of an egg from a carrier of a 
mitochondrial disease) prevents the transmission of a mitochondrial disease 
32. To differentiate between the parents providing the egg and the sperm in this sec-
tion, “mother” refers to the parent providing the egg with mutant mitochondrial DNA. See 
note 1 and accompanying text.
33. See, e.g., Sara Reardon, US Congress Moves to Block Human-Embryo Editing,
NATURE (June 25, 2015), https://www.nature.com/news/us-congress-moves-to-block-human-
embryo-editing-1.17858.
34. Castro, supra note 19, at 728.
35. Id.
36. Tachibana et al., supra note 16, at 425–26.
37. The mother’s nuclear DNA is inserted into the donor egg in the form of a karyo-
plast. See Palacios-González, supra note 7.
38. Tachibana et al., supra note 16, at 426.
39. See, e.g., id. at 425.
40. See id.
41. Taylor & Turnbull, supra note 18, at 389.
42. See Mary Herbert & Doug M. Turnbull, Progress in Mitochondrial Replacement 
Therapies, 19 NATURE REVS. MOL. CELL BIOL. 71, 71 (2018).
43. While this is not a settled issue, this note follows the legal framework of the United 
Kingdom in which the donor has, through informed consent, relinquished parental rights.
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to the offspring.
44
The mother’s nuclear DNA is inserted into the donor egg 
and so the mother’s nuclear DNA is passed on to the child. There is a risk 
that some residual mutant mtDNA from the carrier is still passed down to 
the child, but since the threshold for disease pathology is typically sixty per-
cent, a slight residual amount of mutant mtDNA is not a concern.
45
Additionally, some research teams are modifying the MRT method to 
account for this concern. One team has conducted experiments using polar 
bodies rather than the mother’s oocyte as the source of the mother’s nuclear 
DNA, as discussed above.
46
Polar bodies are nonviable byproducts of meio-
sis in female sex cell division. Polar bodies contain the same nuclear DNA 
as a mature oocyte, however, they contain significantly fewer organelles, 
including mitochondria,
47
and the risk of carryover of the mother’s mutant 
mtDNA is much lower.
48
The procedure of visualizing and manipulating a 
polar body is easier because it is membrane-enclosed.
49
This study had un-
detectable levels of mutant donor mtDNA in all offspring, and so the use of 
polar bodies looks to be a feasible and promising method of carrying out 
MRT in the future.
50
3. MRT Trials in Animals Have Been Successful
MRT was initially tested in primate oocytes
51
and then in mice, and 
successfully prevented the mother from passing on a significant amount of 
mutant mtDNA to the offspring, which prevented the development of 
mtDNA diseases.
52
This therapy has since been validated by multiple teams 
in nonhuman trials.
53 In vitro MST tests involving healthy donor oocytes re-
sulted in almost complete transfer of cytoplasm, which is sufficient to pre-
vent mtDNA disease presentation.
54
In the initial MST trials, approximately 
half of the zygotes had abnormal fertilization,
55
however, after adjusting ex-
44. NAT’L ACADS. Report, supra note 17.
45. Tachibana et al., supra note 16, at 426.
46. Wang et al., supra note 6, at 1593.
47. Caroline M. Dalton & John Carroll, Biased Inheritance of Mitochondria During 
Asymmetric Cell Division in the Mouse Oocyte, 126 J. CELL SCI. 2955, 2955 (2013).
48. Wang et al., supra note 6, at 1593.
49. Id.
50. Id. at 1601.
51. The studies were conducted using rhesus macaque oocytes.
52. Tachibana et al., supra note 16, at 426.
53. See generally Masahito Tachibana et al., Towards Germline Gene Therapy of In-
herited Mitochondrial Diseases, 493 NATURE 627 (2013); Eunju Kang et al., Mitochondrial 
Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations, 540 
NATURE 270 (2016).
54. Tachibana et al., supra note 16, at 427.
55. Tachibana et al., supra note 53, at 630.
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perimental conditions, fertilization was improved.
56
Feasibility and efficacy 
of MST has been confirmed by other independent laboratories.
57
Recent MRT experiments by the MST method have eliminated inherit-
ed mtDNA variants in the embryos of nonhuman primates and humans.
58
The primate offspring had minimal carryover of mutant mtDNA, as did the 
human embryonic stem cells, though the human embryos did not proceed to 
the implantation stage.
59
The spindle apparatus that must be removed from 
the mother’s egg and inserted into the donor’s egg is sensitive, so the results 
of this procedure depend on the operator.
60
Preliminary studies on the pronuclear transfer method of MRT in mouse 
embryos were effective at eradicating mutant phenotypes related to mtDNA 
mutations.
61
However, these studies found that 300 days after birth, the mice 
had five percent to forty-four percent mutant mtDNA, due to amplification 
of residual mutant mtDNA.
62
When the mother’s nucleus is inserted into the 
donor egg, some of the mother’s mutant mtDNA ends up in the combined 
embryo.
63
This occurs because the separation of the nucleus from the rest of 
the cell is a physical process, and a perfect split between the nucleus and the 
cell cytoplasm is not usually achievable.
64
There will often be a small 
amount of cytoplasm surrounding the nucleus after it is removed, and this 
may contain a residual amount of the mother’s mutant mtDNA.
65
Residual 
mutant mtDNA is replicated within the embryo by the same mechanisms as 
the rest of the normal mtDNA, and so a residual amount of mutant mtDNA 
can become a more substantial amount of mutant mtDNA over the time it 
takes to complete many replications.
66
This level of mutant mtDNA does not 
usually cause mutant phenotypes.
67
Studies on pronuclear transfer in hu-
mans has shown minimal carryover of mutant mtDNA to the early em-
56. Kang et al., supra note 53, at 271–72.
57. See Daniel Paull et al., Nuclear Genome Transfer in Human Oocytes Eliminates 
Mitochondrial DNA Variants, 493 NATURE 632, 632 (2013); see also Masahito Tachibana et 
al., Chromosome Transfer in Mature Oocytes, 5 NATURE PROTOCOLS 1138, 1138–39 (2010).
58. Paull et al., supra note 57, at 632; see also Masahito Tachibana et al., Mitochondri-
al Gene Replacement in Primate Offspring and Embryonic Stem Cells, 461 NATURE 367, 371 
(2009); see generally Tachibana et al., supra note 53.
59. Paull et al., supra note 57, at 632; Tachibana et al., supra note 53, at 628.
60. Tomoya S. Kitajima et al., Complete Kinetochore Tracking Reveals Error-Prone 
Homologous Chromosome Biorientation in Mammalian Oocytes, 146 CELL 568, 579 (2011).
61. Akitsugu Sato et al., Gene Therapy for Progeny of Mito-Mice Carrying Pathogenic 
mtDNA by Nuclear Transplantation, 102. PROC. NAT’L ACAD. SCIS. U.S. 16765, 16765 
(2005).
62. Id. at 16768.
63. Tachibana et al., supra note 16, at 425.
64. Wang et al., supra note 6, at 1593.
65. Tachibana et al., supra note 16, at 425.
66. Wang et al., supra note 6, at 1591.
67. See id.
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bryo.
68
Because of the restrictions on research and clinical trials on MRT, 
scientists do not have much data on the carryover of mutant mtDNA in hu-
mans who receive MRT. This is an area that requires further study.
B. Current Treatment Options for Women Who Are Carriers of
Mitochondrial Diseases
A woman who has some mutant mtDNA but does not exhibit a mito-
chondrial disease is called a carrier. When a woman is a carrier, she can use 
typical screening methods such as preimplantation genetic diagnosis to see 
if she has passed on mutant mtDNA to her baby. Preimplantation genetic 
diagnosis can identify genetic abnormalities in an embryo, but it is only a 
diagnostic tool, not a treatment. These screening methods may not be able to 
accurately identify whether the mutant mtDNA has led to a mitochondrial 
disease.
69
If a woman is a carrier for a mitochondrial disease and does not 
want to risk passing the condition on to a child, the only current options are 
adopting or using an egg donor.
70
While a treatment to address the problem 
of potentially passing on mitochondrial diseases is developing rapidly, it is 
not approved in the United States at this time. Currently, there is no way for 
a carrier of mtDNA diseases in the United States to have a child to whom 
she is biologically related without risking mitochondrial disease.
II.  United States Regulation Of Gene, Cell, And Embryo 
Therapies
In the United States, research on mitochondrial diseases and potential 
treatments have stalled because of federal regulations. The regulatory land-
scape is controlled by the Dickey-Wicker Amendment and the Food, Drug, 
and Cosmetic Act (FDCA), both of which have created substantial road-
blocks to the progression of research and clinical trials.
71
A. Human Cells, Tissues, and Cellular and Tissue Based Products 
(HCT/Ps)
The FDA regulates Cell and Gene Therapies (CGT) under the Center 
for Biologics Evaluation and Research (CBER) in the Office of Tissues and 
68. Lyndsey Craven et al., Pronuclear Transfer in Human Embryos to Prevent Trans-
mission of Mitochondrial DNA Disease, 465 NATURE 82, 84 (2010).
69. Annelien L. Bredenoord et al., PGD to Reduce Reproductive Risk: The Case of Mi-
tochondrial DNA Disorders, 23 HUM. REPROD. 2392, 2392 (2008).
70. Gretchen Vogel, For Boys Only? Panel Endorses Mitochondrial Therapy, but Says 
Start with Male Embryos, SCIENCE (Feb. 3, 2016, 2:00 PM), https://www.sciencemag.org
/news/2016/02/boys-only-panel-endorses-mitochondrial-therapy-says-start-male-embryos.
71. Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, § 128, 110 Stat. 26, 34 
(1996); 21 U.S.C. §§ 301–399i (2018).
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Advanced Therapies.
72
The CBER mission is, “to protect and enhance the 
public health through the regulation of biological and related products in-
cluding blood, vaccines, allergenics, tissues, and cellular and gene thera-
pies.”
73
CBER’s statutory authority comes from the Public Health Service 
(PHS) Act
74
and the Food, Drug and Cosmetic Act (FDCA).
75
Under the 
FDCA and PHS Act, the FDA has the authority to regulate genetically ma-
nipulated cells and their derivatives.
76
For MRT, the pertinent type of biological products are Human Cells, 
Tissues, and Cellular and Tissue Based Products (HCT/Ps). There are two 
types of HCT/Ps: 351 HCT/Ps and 361 HCT/Ps. 361 HCT/Ps are only regu-
lated under § 361 of the PHS Act
77
and 21 C.F.R. § 1271. 361 HCT/Ps are
not a class of products; § 361 gives the FDA authority to make and enforce 
regulations that prevent the introduction, transmission, and spread of com-
municable diseases from foreign countries into the United States.
78
361 
HCT/Ps are not subject to premarket approval.
79
In order to be a 361 HCT/P, 
the product must meet the criteria outlined in 21 C.F.R. § 1271.10(a). These 
criteria are:
(1) the HCT/P is minimally manipulated, (2) intended for homolo-
gous use only . . . (3) the manufacture does not involve the combi-
nation of the cells or tissues with another article . . . and, (4) either: 
(i) the HCT/P does not have a systemic effect and is not dependent 
upon the metabolic activity of living cells for its primary function; 
or (ii) the HCT/P has a systemic effect or is dependent upon the 
metabolic activity of living cells for its primary function, and: (a) is 
for autologous use; (b) is for allogeneic use in a first-degree or sec-
ond-degree blood relative; or (c) is for reproductive use.
80
In its draft guidance for industry, the FDA says that reproductive cells 
and tissues such as embryos, semen, and oocytes are 361 HCT/Ps that meet 
72. Michael Mendicino et al., Current State of U.S. Food and Drug Administration 
Regulation for Cellular and Gene Therapy Products: Potential Cures on the Horizon, 21 
CYTOTHERAPY 699, 699 (2019).
73. About CBER, FDA (Feb. 6, 2018), https://www.fda.gov/about-fda/center-biologics-
evaluation-and-research-cber/about-cber.
74. See 42 U.S.C. § 262(a)(2) (2018).
75. See 21 U.S.C. §§ 301–399i (2018).
76. Therapeutic Cloning and Genome Modification, FDA (Mar. 16, 2018), 
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/therapeutic-
cloning-and-genome-modification.
77. See 42 U.S.C. § 264 (2018).
78. 21 C.F.R. § 1271.1(a) (2020).
79. See 42 U.S.C. § 264 (2012); 21 C.F.R. § 1271 (2020); CTR. BIOLOGICS 
EVALUATION & RSCH., FDA, REGULATION OF HUMAN CELLS, TISSUES AND CELLULAR AND 
TISSUE-BASED PRODUCTS (HCT/PS) – SMALL ENTITY COMPLIANCE GUIDE: GUIDANCE FOR 
INDUSTRY (2007) [hereinafter FDA HCT/PS GUIDE].
80. 21 C.F.R. § 1271.10(a) (2020).
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the criteria outlined in § 1271.10(a).
81
On this basis, it may seem that MRT 
products qualify as 361 HCT/Ps. However, the egg or embryo resulting 
from MRT does not meet §1271.10(a)’s minimal manipulation requirement 
because it combines portions of two different eggs. “Minimal manipulation”
is defined as “processing that does not alter the relevant biological charac-
teristics.”
82
As the nuclear DNA is replaced in the embryo, the biological 
characteristics are altered, so MRT embryos fail to meet all of the 361 
HCT/P requirements.
There are exceptions listed in 21 C.F.R. § 1271.15 whereby certain 
HCT/Ps are exempt from regulatory requirements. Only exception (e) is rel-
evant to MRT, which says, “you are not required to comply with the re-
quirements of this part if you are an establishment that only recovers repro-
ductive cells or tissues and immediately transfers them into a sexually 
intimate partner of the cell or tissue donor.” Normal IVF procedures qualify 
under this exemption, however MRT does not qualify because the cell that 
is implanted into the mother contains more than just cells from her intimate 
sexual partner, it also contains a cell fragment from an egg donor.
Because the embryo created by MRT does not qualify as a 361 HCT/P 
under § 1271.10(a), nor does it qualify for a § 1271.15 exemption, an em-
bryo created by MRT would be a 351 HCT/P if MRT was legally allowed in 
the United States (as discussed in Part III). 351 HCT/Ps are biological drugs 
under § 351 of the PHS Act,
83
regulated under 21 C.F.R. § 1271.20, and 
qualify as “drugs” under the Food, Drug, and Cosmetic Act (FDCA).
84
This 
means that if MRT were legal, it would be subject to the premarket and 
post-market requirements of biological drugs. For a 351 HCT/P, a Biologics 
License Application (BLA) is required. The BLA requests permission to in-
troduce a biologic product into interstate commerce and sets out the re-
quirements for filing.
85
Before a clinical trial can proceed on a 351 HCT/P, 
the sponsor must submit an Investigational New Drug (IND) application to 
the FDA.
86
The same as any other IND application, it must comply with the 
regulations set forth in Title 21 of the Code of Federal Regulations (CFR), 
parts 50, 56, and 312.
87
81. FDA HCT/PS GUIDE, supra note 79, at 4.
82. 21 C.F.R. § 1271.3 (2020).
83. See 42 U.S.C. § 262(i) (2018).
84. See 21 U.S.C. § 321(g)(1)(B) (2018) (defining “drugs” as “articles intended for use 
in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other ani-
mals”).
85. 21 C.F.R § 601.2 (2019).
86. FDA, supra note 76.
87. Id.
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B. The Congressional Ban of MRT
In 2014, the FDA held a meeting of the Cellular, Tissue and Gene 
Therapy Advisory Committee (CGTAC) to consider the permissibility of 
oocyte and embryo modification as a treatment for infertility or a method of 
preventing the inheritance of mitochondrial diseases.
88
This meeting con-
cluded that there was insufficient evidence to prove that the technique was 
safe enough for research to proceed in humans.
89
The FDA concluded that 
there was insufficient animal data for MRT to move on to clinical trials in 
humans.
90
In 2015, the FDA requested that the Institute of Medicine (IOM) write a 
consensus report on the ethical and social concerns related to genetic modi-
fication of embryos as a treatment for mitochondrial diseases.
91
In 2016, the 
IOM published a report on the ethical concerns of MRT concluding that 
MRT is ethically permissible as long as specific conditions and principles 
are met, as discussed below.
92
The report emphasized the benefits in terms 
of reproductive options that MRT provides to women who are carriers of 
mtDNA diseases.
93
The report recommended limiting MRT to women who 
are at risk of transmitting an mtDNA disease that is likely to manifest in a
way that is severely pathological to their child.
94





resulting in male embryos would not be classified as a therapy that produces 
a heritable genetic modification because males do not pass on their mtDNA 
88. Id.
89. FDA, BRIEFING DOCUMENT, OOCYTE MODIFICATION IN ASSISTED REPRODUCTION 







90. Sharon Begley, U.S. FDA Weighs Evidence on Producing ‘Three-Parent’ Embryos, 
REUTERS (Feb. 25, 2014), https://www.reuters.com/article/usa-health-ivf/u-s-fda-weighs-
evidence-on-producing-three-parent-embryos-idUSL1N0LU1OI20140225.
91. FDA, supra note 76.
92. NAT’L ACADS. SCIS., ENG’G & MED., MITOCHONDRIAL REPLACEMENT 
TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 117 (2016) [hereinafter 
NAT’L ACADS. CONSIDERATIONS].
93. Id. at 118.
94. Id. at 119.
95. The report refers to “male” embryos and “female” embryos, however, the distinc-
tion is actually between XY and XX embryos. XY embryos are genotypically male and XX 
embryos are genotypically female, and the report’s suggestion is that XY embryos will devel-
op into people who cannot pass on mtDNA to their children. This is not true in all cases. Dis-
cussed below.
96. NAT’L ACADS. CONSIDERATIONS, supra note 92, at 120.
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to their offspring.
97
Limiting MRT to male embryos eliminates the risk of 
passing on an unexpected pathology resulting from MRT to future off-
spring. The report notes that such limitation would be valuable in the early 
experimental stage because unforeseen consequences of the therapy may 
present in the first generation of patients, and these issues can be addressed 
before impacting a second generation.
98
This raises ethical concerns sur-
rounding female embryos and whether the FDA can require parents to select 
the sex of their child.
99
Additionally, the report itself acknowledges that if 
preclinical research is only carried out to produce male offspring, the risks 
associated with female offspring resulting from MRT cannot be resolved.
100
In making this recommendation, the committee reasoned that the tradeoffs 
of only conducting preclinical MRT research with male embryos are both 
necessary and justified in order to eliminate the risk of passing on detri-
mental heritable genetic modifications to a second generation.
101
The Chair of the CGTAC Committee, Jeffrey Kahn, said, “in examining 
the ethical, social, and policy issues associated with mitochondrial replace-
ment techniques, we concluded that the most germane issues could be 
avoided if the use of these techniques were restricted by certain conditions, 
rather than prohibiting them altogether.”
102
While the Committee cautiously recommended that MRT testing could 
proceed, Congress halted any progress. In 2016, Congress passed the Agri-
culture, Rural Development, Food and Drug Administration, and Related 
Agencies Appropriations Bill, which contained a rider barring the FDA 
from considering requests to approve clinical trials in which a human em-
bryo is intentionally created to include a heritable genetic modification.
103
Because of this rider, the FDA cannot accept INDs that involve germline 
modifications. The final version of the rider, which has been incorporated 
into the annual appropriations bill in every subsequent year, states:
None of the funds made available by this Act may be used to notify 
a sponsor or otherwise acknowledge receipt of a submission for an 
exemption for investigational use of a drug or biological product 
under section 505(i) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(i)) or section 351(a)(3) of the Public Health Service 
Act (42 U.S.C. 262(a)(3)) in research in which a human embryo is 
97. Id. at 119.
98. Id.
99. Castro, supra note 19, at 732.
100. NAT’L ACADS. CONSIDERATIONS, supra note 92, at 120.
101. Id. at 121.
102. NAT’L ACADS. Report, supra note 17.
103. Jocelyn Kaiser, Update: House Spending Panel Restores U.S. Ban on Gene-Edited 
Babies, SCIENCE (June 4, 2019, 1:45 PM), https://www.sciencemag.org/news/2019/06/update-
house-spending-panel-restores-us-ban-gene-edited-babies#:~:text=It%20bars%20the%20Food
%20and,human%20germline%20editing%E2%80%94or%20the.
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intentionally created or modified to include a heritable genetic 
modification. Any such submission shall be deemed to have not 
been received by the Secretary, and the exemption may not go into 
effect.
104
The rider barring FDA review of clinical trials involving genetic modi-
fication of human embryos was briefly repealed in 2019. A draft of the 2020 
spending bill that was approved by the Democrat-led House appropriations 
subcommittee did not contain the rider. After the draft was released a Dem-
ocratic aide, speaking with Science Insider, said that the rider was dropped 
because, “it was inserted in private 3 years ago and has never been subject 
to public debate. We believe this provision could limit important scientific 
research and, if Congress chooses to prohibit such research, that should be 
done in the light of day.”
105
Only a few months later, the rider was reinstated 
by the full Appropriations Committee of the U.S. House of Representatives 
as the request of the Republicans.
106
The only member who did not vote in 
favor of restoring the rider was Democrat Debbie Wasserman-Schultz.
107
Some Democrats were reluctant to reinstate the rider and some lawmakers 
on both sides agree that the issue should be subject to fuller debate and 
analysis by congressional health committees.
108
III.  Research And Clinical Trials On Mitochondrial 
Replacement Therapy Should Be Allowed in the United States
The rider in the Agriculture, Rural Development, and Food and Drug 
Administration and Related Agencies Appropriations Bill has never been 
fully and publicly debated. It has not been subject to notice and comment, 
and a full and thoughtful debate amongst lawmakers with perspectives from 
experts and regulatory agencies to which this ban applies.
In order to accomplish Congress’s goal of prohibiting gene editing, the 
rider should be amended. This note suggests amending the language of the 
rider as follows:
None of the funds made available by this Act may be used to notify 
a sponsor or otherwise acknowledge receipt of a submission for an 
exemption for investigational use of a drug or biological product 
under section 505(i) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(i)) or section 351(a)(3) of the Public Health Service 
Act (42 U.S.C. 262(a)(3)) for research in which a heritable genetic 
104. H.R. 648, 116th Cong. § 733 (2019).
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modification is achieved by creating an artificial DNA sequence.
Any such submission shall be deemed to have not been received by 
the Secretary, and the exemption may not go into effect.
This modification to the rider would allow the FDA to review and ap-
prove INDs for MRT. MRT does not alter the DNA sequence of mtDNA or 
nuclear DNA—it simply combines different parts of two separate eggs, each 
with their respective mtDNA or nuclear DNA completely unaltered.
A. MRT is Legal in Other Countries and Has Produced Positive Results
While the United States is debating the legality and ethics of this inno-
vate therapy, a few other countries are making great advancements in MRT 
research. The United Kingdom, Greece, and Ukraine are leading the field. 
Each of these countries have clinics at which MRT is performed for women 
who wish to have a genetically related child but have had difficulty because 
the mother is either a carrier for a mitochondrial disease or struggles with 
infertility. Other countries such as Spain, Singapore, and Mexico are explor-
ing MRT, but are in the preliminary research phase and have not yet moved 
to the clinical stage. There is support across the globe for progression of this 
therapy.
1. MRT Is Legal in the United Kingdom as a Clinical Procedure for 
Assisted Reproduction
In the United Kingdom, the Human Fertilization Act (HFE Act) gov-
erns regulations of mitochondrial replacement therapy and all other repro-
ductive technologies.
109
The regulatory body, Human Fertilization and Em-
bryology Authority (HFEA), which was created in 1990, oversees 
reproductive technology.
110
HFEA regulates assisted reproduction and em-
bryo research.
111
HFEA has the power to determine and regulate what is 
“permitted” assisted reproduction.
112
The 2015 amendments to the 1990 
HFE Act expanded to include mitochondrial replacement therapy as a per-
mitted reproduction technique and allowed for “mitochondrial donor-
conceived person[s].”
113
The 2015 amendment to the HFE Act allowed MRT as part of an in 
vitro fertilization technique, and subsequently, clinical trials on MRT be-
gan.
114
The amendment also declared that mitochondrial donors do not have 
109. Castro, supra note 19, at 728.
110. Id.
111. Vogel, supra note 70.
112. Castro, supra note 19, at 728.
113. The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 
2015, SI 2015/572, pt. 2.
114. See id.
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parental rights.
115
A child born from MRT is allowed limited access to in-
formation about the mitochondrial donor, but this information will not iden-
tify the donor, and the child is not provided any information about other 
children from the same donor.
116
Similarly, the donor can access a limited 
amount of non-identifying information about children born from their dona-
tion.
117
This amendment also declared that once the egg or embryo is pro-
duced with the donor’s egg, with informed consent, it is no longer consid-
ered the egg or embryo of the mitochondrial donor for consent purposes, 
and at this point consent can no longer be withdrawn.
118
HFEA granted a pa-
tient license in 2017, and now MRT can be done outside of clinical trials.
119
HFEA now allows fertility clinics to offer MRT on a case-by-case basis 
with close HFEA oversight.
120
HFEA ensures that patients for all types of 
assisted reproduction provide informed consent and carefully weigh their 
options prior to making a decision.
121
Prior to the implementation of the 2015 amendment, HFEA undertook a 
public and stakeholder consultation to “review the ethical, social and regula-
tory issues involved in the clinical use of techniques for mitochondrial re-
placement.”
122
This consultation informed the advice HFEA gave the legis-
lature for consideration when amending the HFE Act.
123
HFEA continuously 
meets throughout the year to evaluate and modify policies and practices for 
assisted reproduction.
124
HFEA has committees and panels of members, 
staff, and the general public.
125
2. Greece and Ukraine Have Had Successful Births Through MRT
In Greece and Ukraine, MRT is legally used to treat infertility.
126
In 
Greece, a healthy baby conceived through MRT treatment was born in April 
115. The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 
2015 pt. 3.
116. Id.
117. Castro, supra note 19, at 728.
118. Id.
119. Ian Sample, UK Doctors Select First Women to Have ‘Three-Person Babies’,
GUARDIAN (Feb. 1, 2018, 1:48 PM), https://www.theguardian.com/science/2018/feb/01
/permission-given-to-create-britains-first-three-person-babies.
120. Vogel, supra note 34.
121. Consent to Treatment, HUM. FERTILISATION & EMBRYOLOGY AUTH., 
https://www.hfea.gov.uk/choose-a-clinic/consent-to-treatment (last visited Feb. 17, 2021).
122. Diane Warburton, Tracing the Impacts of Public Dialogue Projects Supported by 
Sciencewise: Mitochondrial Replacement, SCIENCEWISE (Mar. 2016).
123. Id.
124. About Us, HUM. FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk
/about-us/our-authority-committees-and-panels (last visited Feb. 17, 2021).
125. Id.
126. E.g., Mullin, supra note 4.
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2019. A maternity clinic in Athens is licensed by the National Medically 
Assisted Reproduction Authority to perform clinical trials on MRT.
127
In Kiev, Ukraine, a private fertility clinic called the Nadiya Clinic per-
forms MRT.
128
Since the Clinic opened, Dr. Valery Zukin has performed 
twenty-one MRT procedures.
129
Fourteen of these procedures were unsuc-
cessful in implanting the embryo into the mother; however, the clinic be-
lieves that this was due to the age of the mother and the increased difficulty 
of getting pregnant as a woman gets older.
130
The seven remaining MRT 
procedures performed at the Nadiya Clinic resulted in four successful and 
healthy births, and three more pregnancies were in progress when Dr. Zukin 
reported his success in June 2018. No further information on the success of 
these pregnancies has been reported.
131
3. Other Countries, Including Spain and Singapore, Are Considering 
Legalizing MRT
Spanish researchers are investigating MRT as a treatment for infertility. 
Clinical trials are being carried out in Greece in collaboration with a Span-
ish company.
132
Singapore is considering legalizing MRT.
133
Currently, Sin-
gapore does not allow human germline modifications in the clinical setting, 
but it allows gene editing for research, and so MRT can be done as a part of 
a research study.
134
B. MRT is Distinct from the Types of Therapies That Have Been Met 
with the Most Vehement Societal Opposition
There are a variety of therapies that involve genetic modifications, and 
they all raise unique ethical questions. There are particularly strong con-
cerns regarding “new eugenics” and “designer babies,” which are multifac-
127. MST Research, INST. LIFE, https://www.iolife.eu/en/us/mst-research (last visited 
Apr. 2, 2021).
128. Rob Stein, Clinic Claims Success in Making Babies with 3 Parents’ DNA, NPR
(Jun. 6, 2018, 5:11 AM), https://www.npr.org/sections/health-shots/2018/06/06/615909572
/inside-the-ukrainian-clinic-making-3-parent-babies-for-women-who-are-infertile.
129. Id.
130. Id. A study conducted by the Nadiya Clinic doctors and presented at a Philadelphia 
meeting of the American Society of Reproductive Medicine concluded that MRT was not ef-
fective at increasing the fertility of women age thirty-seven and older. See Pavlo Mazur et al., 
Mitochondrial Replacement Therapy Give No Benefits to Patients of Advanced Maternal Age,
112 FERTILITY & STERILITY, Sept. 2019, at e193, e193.
131. Stein, supra note 128.
132. See Mullin, supra note 4.
133. Sandy Ong, Singapore Could Become the Second Country to Legalize Mitochon-
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eted.
135
The process and potential applications of these types of therapies are 
distinct from MRT, as discussed below. Handpicking traits is not something 
that can be achieved through MRT. The result of the rider is that it encom-
passes and prevents progress on a broader array of reproductive technolo-
gies. MRT has been classified as germline therapy by some experts,
136
and 
not germline therapy by others.
137
This inconsistency calls into question 
whether the ban should apply to MRT. MRT is a substantially different pro-
cess from gene editing technologies such as Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR).
138
The methods and potential future 
applications of CRISPR are different from those of MRT. Gene editing 
technologies alter the actual DNA sequence. This modifies the genes that 
are expressed, and the proteins coded from these genes, which ultimately 
affects physical traits. With MRT, the nuclear and mitochondrial DNA se-
quences are completely unaltered. The goal of gene editing therapies such as 
CRISPR is to alter the expression or presence of certain heritable traits by 
targeting the DNA sequences encoding specific characteristics. The goal of 
MRT is to replace the entire mutated mitochondrial DNA sequence of the 
parent with a healthy, normal mtDNA sequence from a donor.
The plain language of the rider does not specifically ban editing of 
gametes,
139
as the rider uses the language “embryo,” not “gamete,” “sperm,”
or “egg.” Looking at the plain language, the rider banning intentional modi-
fication of human embryos may not strictly apply to techniques such as 
MRT that do not modify an embryo, but a precursor. University of Illinois 
at Urbana-Champaign law professor Jacob S. Sherkow says:
135. See Michael R. Dohn, Preventing an Era of “New Eugenics”: An Argument for 
Federal Funding and Regulation of Gene Editing Research in Human Embryos, 25 RICH. J.L
& TECH. 1, 21–22 (2018); see also Peter H. Huang, Herd Behavior in Designer Genes, 34 
WAKE FOREST L. REV. 639, 640 (1999); Alexandra M. Franco, Transhuman Babies and Hu-
man Pariahs: Genetic Engineering, Transhumanism, Society and the Law, 37 CHILD LEGAL 
RTS. J. 185, 185–86, 190 (2017).
136. NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION OF 
MITOCHONDRIAL DNA DISORDERS: AN ETHICAL REVIEW 58 (2012) (stating that MRT is not 
intended to modify nuclear genes or change the donor’s mitochondrial DNA, but to replace 
the mother’s mitochondria).
137. NAT’L ACADS. CONSIDERATIONS, supra note 92, at 6–7, 62 (stating that “genetic 
modification” means “changes to the genetic material within a cell.” However, the report de-
fined germline modification as that entailing “heritable modifications” and so the process of 
MRT to create a male offspring is not germline modification).
138. CRISPRs are DNA sequences from prokaryotic organisms such as bacteria. These 
DNA sequences are associated with an enzyme, Cas9, which cuts DNA at a specific sequence. 
The CRISPR-Cas9 system can be used to cut out and replace specific DNA sequences in a 
human’s DNA sequence. This has the potential to cure a genetic disease or disorder. Aparna 
Vidyasagar, What Is CRISPR?, LIVE SCI. (Apr. 21, 2018), https://www.livescience.com
/58790-crispr-explained.html.
139. Sperm and egg cells.
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The debate was firmly centered on the editing of embryos, but no 
legislator considered whether the language also applied to the edit-
ing of sperm and eggs . . . and there are strong arguments to be 
made that the plain text of the rider does not apply to sperm and 
eggs.
140
Religious and political opposition to gene editing are less vehement 
when it comes to the modification of sperm and egg cells, as opposed to 
embryos.
141
The Dickey-Wicker Amendment took on the issue of destroying 
human embryos for research and clinical settings.
142
Parallel objections to 
the destruction of sperm and egg cells have not been raised.
143
According to 
Sherkow, “the current federal funding ban is predicated on a concept of bio-
ethics that focuses on the embryo, and that’s because there’s widespread 
recognition in U.S. society that embryos have a certain moral salience that 
other biological components don’t.”
144
Much of the opposition to gene editing technology, and precursory pro-
cedures such as embryonic stem cell therapy, was based on the fact that in
order to pursue this research and the resulting clinical procedures, an em-
bryo needs to be destroyed. Those who believe in embryonic personhood 
claim that personhood begins when the sperm and egg combine to form a 
zygote.
145
Forms of MRT, such as maternal spindle transfer, that modify the 
egg or sperm prior to fertilization, and so occur before the formation of the 
embryo. MRT therefore precedes personhood from the embryo personhood 
perspective. A sperm or egg alone cannot become a viable human, and this 
makes them analytically and biologically distinct from embryos.
C. Removing the Rider Simply Enables the FDA to Perform Its Job and 
Evaluate Applications for Clinical Trials
Some researchers and scientific advocacy groups oppose the rider be-
cause Congress made the decision, not scientific and regulatory experts.
146
Sean Tipton, chief advocacy, policy, and development officer at the Ameri-
140. Univ. of Ill. at Urbana-Champaign, News Bureau, Paper: Congress Must Clarify 
Limits of Gene-Editing Technologies, EUREKALERT! (Oct. 21, 2020), 
https://www.eurekalert.org/pub_releases/2020-10/uoia-pcm102120.php.
141. I. Glenn Cohen et al., Gene Editing Sperm and Eggs (not Embryos): Does it Make a 
Legal or Ethical Difference?, 48 J.L MED. & ETHICS 619, 619 (2020).
142. See id.
143. See id.
144. Univ. of Ill. at Urbana-Champaign, News Bureau, supra note 140.
145. Id. Many states have introduced “personhood” initiatives which have attempted to 
equate an embryo with a person who has legal rights. These laws have all been rejected by 
voters and legislatures, however, they continue to be filed and debated. Editorial, The “Per-
sonhood” Initiative, N.Y. TIMES (Oct. 27, 2011), http://www.nytimes.com/2011/10/28
/opinion/the-personhood-initiative.html.
146. Kaiser, supra note 103.
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can Society for Reproductive Medicine says “[the provision was] an anti-
science rider” and that “[removing it] allows the FDA to do its job.”
147
The current rider prevents scientists from conducting the research that is 
necessary to determine if it may one day be safe and effective to genetically 
modify embryos to prevent inherited genetic diseases.
148
In 2018, the FDA 
and National Institutes of Health (NIH) said that “[i]n the view of the senior 
leaders of the FDA and NIH, there is no longer sufficient evidence to claim 
that the risks of gene therapy are entirely unique and unpredictable—or that 
the field still requires special oversight that falls outside our existing 
framework for ensuring safety.”
149
If the rider were modified so that the ban does not encompass MRT, 
this therapy would be considered a 351 HCT/P and would be regulated by 
the FDA the same as other biological drugs. It would be subject to pre-
market and post-market approval, a sponsor for a clinical trial would need to 
submit a biologics license application and an investigational new drug ap-
plication, and the biologic would be subject to all of the safeguards the FDA 
has in place to ensure safety and efficacy. Modifying the rider would not 
mean that MRT would be available immediately. It would mean that re-
searchers who wish to perform clinical trials would be able to apply to the 
FDA for approval and begin the process of investigating the safety and effi-
cacy of this therapy.
D. Political and Legislative Resistance is Based on Past Therapies that 
are Unrelated to MRT
Congressman Jeff Fortenberry (R-NE) opposes removing the FDA rider 
barring embryo modification, and said “starting in 2016, the subcommittee 
acted to prevent an emerging science that would allow for the permanent 
modification of an individual’s genetics and those of future offspring. This 
is a prohibition that is accepted by nearly every nation in the world due to
the unknown risks.”
150
Congresswoman Kay Granger (R-TX) also supported 
the ban, saying “it would be irresponsible for us to fund FDA’s review of 
this very risky research.”
151
Congressman Robert Aderholt (R-AL) said, 
“There are just too many unknowns . . . . Many of us believe it’s just a step 
too far too soon.”
152
There is some credence in this fear of the unknown be-
cause of unrelated experimental gene therapies which did not result in via-
147. Id.
148. Rob Stein, House Committee Votes to Continue Ban on Genetically Modified Ba-
bies, NPR (June 4, 2019, 4:38 PM), https://www.npr.org/sections/health-shots/2019/06/04
/729606539/house-committee-votes-to-continue-research-ban-on-genetically-modified-babies.
149. Francis S. Collins & Scott Gottlieb, The Next Phase of Human Gene-Therapy 
Oversight, 379 NEW. ENG. J. MED. 1393, 1393 (2018).
150. Kaiser, supra note 103.
151. Stein, supra note 148.
152. Id.
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ble treatment procedures. Even so, scientific progress and valuable medical 
advances such as MRT can only be achieved by researching what its un-
known. This is the foundation of scientific discovery.
1. Issues with Past Unrelated Gene Therapies
Gene therapies have a complicated history that is distinct from the mer-
its of new therapies. Earlier gene therapies came under scrutiny for safety 
concerns and unknown efficacy. In the 1990s, the United States conducted 
research on cytoplasmic transfer in an attempt to improve a woman’s
chances of successful IVF after numerous failed implantations attempts.
153
This technique involved injecting cytoplasm from a donor egg into the 
mother’s egg prior to IVF.
154
Research into cytoplasmic transfer was 
stopped after two children born through this process had chromosomal 
anomalies and one child had a serious developmental disorder.
155
Because of 
the chromosomal abnormalities and birth defects the FDA, which has regu-
lated gene therapy since 1990,
156
banned cytoplasmic transfer due to safety 
concerns.
157
In 1999, an eighteen-year-old volunteer died in a Phase I clinical trial 
for a gene therapy designed to treat ornithine transcarbamylase deficiency, a 
rare and fatal X-linked disease.
158
Although mitochondrial replacement ther-
apy is not strictly a gene therapy in the sense that genes are not modified, it 
has been associated with gene therapy and the accompanying concerns.
Compared to other countries such as the United Kingdom, the United 
States has not consulted the public.
159
This may be in part due to fears over 
the controversial nature of therapies involving human embryos. Discussions 
in the United States relating to MRT and other assistive reproductive tech-
nologies have been conflated with abortion and the surrounding controver-
sy.
160
Reproductive rights in the United States have a long history of scruti-
ny based on political and religious values, often making these conversations 
unproductive.
153. Castro, supra note 19, at 727.
154. Id.
155. NUFFIELD COUNCIL ON BIOETHICS, supra note 136.
156. The first human gene therapy clinical trial the FDA oversaw was a pediatric study 
on adenosine deaminase deficiency, carried out in Bethesda, Maryland at the NIH Clinical 
Center. Collins & Gottlieb, supra note 149, at 1393.
157. Tachibana et al., supra note 16, at 424.
158. Jesse Geslinger is the first person reported to have died in an FDA approved clini-
cal trial for a gene therapy. Nikunj V. Somia & Inder M. Verma, Gene Therapy: Trials and 
Tribulations, NATURE REVS. GENETICS (2000).
159. I. Glenn Cohen et al., Transatlantic Lessons in Regulation of Mitochondrial Re-
placement Therapy, 348 SCIENCE 178, 180 (2015).
160. Id. at 179.
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2. The Fight Over Stem Cell Research
The policy and ethical issues that MRT currently faces are similar to 
those of human embryonic stem cells (hESC). In the early 2000s, legislation 
prohibited American researchers for investigating hESC, which set back the 
scientific community and slowed the progression of a valuable therapy. The 
current ban on MRT puts this therapy in the same standstill. In 2001, Presi-
dent George W. Bush banned federal funding for research using hESC.
161
Private funding was still eligible for use on this type of research, but this put 
researchers in a difficult position and some resorted to dividing staff, 
equipment, and laboratory space for private and federally funded research.
162
The Bush Administration policy prevented research using embryonic stem 
cells because of the belief that using these cells required the destruction of 
human life.
163
This policy reflected an entire movement of thought support-
ing the notion that life begins in the embryo. In order to isolate embryonic 
stem cells, an embryo must be destroyed. However, scientists extract stem 
cells from the extra embryos created for couples undergoing IVF, and these 
unused embryos would be destroyed by the IVF clinics regardless.
164
This 
ban stifled progress for many researchers. In 2009, President Obama signed 
an executive order that revoked President Bush’s order on embryonic stem 
cells, allowing researchers to proceed with embryonic stem cell research.
165
This allowed researchers to use the extra embryos created from IVF to de-
rive embryonic stem cells.
166
State and private funding allowed continued research of embryonic 
stem cells, but while the federal ban was in place progress was slowed. 
When President Obama issued his executive order, he remarked, “(m)edical 
miracles do not happen simply by accident. They result from painstaking 
161. Varnee Murugan, Embryonic Stem Cell Research: A Decade of Debate from Bush 
to Obama, 82 YALE J. BIOL. & MED. 101, 101 (2009).
162. Id.
163. President Bush was quoted as saying, “at its core, this issue forces us to confront 
fundamental questions about the beginnings of life and the ends of science . . . . My position 
on these issues is shaped by deeply held beliefs . . . I also believe human life is a sacred gift 
from out creator.” Alice Park, George W. Bush and the Stem Cell Research Funding Ban,
TIME (Aug. 20, 2012), https://healthland.time.com/2012/08/21/legitimate-rape-todd-akin-and-
other-politicians-who-confuse-science/slide/bush-bans-stem-cell-research/print.
164. Id.
165. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 11, 2009).
166. Park, supra note 163. A few months later, a lawsuit was filed alleging that Presi-
dent Obama’s Executive Order Violated the Dickey-Wicker amendment. The court ruled for 
the plaintiffs and issued a preliminary injunction that blocked federal funding of human em-
bryonic stem cell research. On appeal, the U.S. Court of Appeals for the D.C. Circuit reversed 
on August 24, 2012, and the plaintiffs appealed to the Supreme Court, who denied to grant 
certiorari. In the 2012 presidential election, this was a point of contention, President Obama 
intended to allow embryonic stem cell research to continue if reelected and Mitt Romney 
would have banned it. See Allen M. Spiegel, The Stem Cell Wars: A Dispatch from the Front,
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and costly research . . . and from a government willing to support that 
work.”
167
The issues concerning MRT are similar to those faced by embryonic 
stem cell researchers. Political and religious opposition to these techniques 
are in complete opposition to researchers who see an opportunity for pro-
gress and to alleviate suffering caused by disease. Studies have concluded 
that the ban on stem cell research set back the scientific community in the 
United States substantially.
168
One study estimates that as a result of the 
Bush administration’s 2001 policy, “U.S. production of hESC [human em-
bryonic stem cell research] lagged 35 to 40 percent behind anticipated lev-
els.”
169
Once President Obama lifted the ban, the stem cell policy was sub-
ject to notice and comment, and regulations were issued by the NIH, the 
governing regulatory body. MRT has not been provided the benefits of these 
procedures.
E. Without FDA Regulation and the Opportunity for Approval, 
Researchers and Patients Will Look Abroad or Conduct MRT Illegally 
and Dangerously
There is currently no federal funding in the US for gene editing in hu-
man embryos. This has led American researchers to go to other countries.
170
In Mexico, MRT is only allowed in research to “solve sterility problems that 
cannot be solved otherwise.”
171
In 2016, an American doctor crossed the 
border and implanted an embryo created through MRT into a Jordanian 
woman who was a carrier for Leigh syndrome.
172
This resulted in a success-
ful birth.
173
Some researchers argue that this procedure was in violation of 
Mexican law because the mother did not technically have unsolvable fertili-
ty problems,
174
but no legal action was taken.
The Dickey-Wicker rider hinders the development of potentially helpful 
therapies, including MRT.
175
Federal funding would allow the government 
oversee regulation and monitor any ethical concerns stemming from this 
167. Barack Obama, President, United States, Remarks of the President: Signing of 
Stem Cell Executive Order and Scientific Integrity Presidential Memorandum (Mar. 9, 2009), 
https://obamawhitehouse.archives.gov/the-press-office/remarks-president-prepared-delivery-
signing-stem-cell-executive-order-and-scientifi.
168. See Jason Owen-Smith & Jennifer McCormick, An International Gap in Human ES 
Cell Research, 24 NATURE BIOTECH. 391, 392 (2006).
169. Jeffrey L. Furam et al., Growing Stem Cells: The Impact of Federal Funding Policy 
on the U.S. Scientific Frontier, 31 J. POL’Y ANALYSIS & MGMT. 661, 661 (2012).
170. See Dohn, supra note 135, at 25.
171. Bartha Maria Knoppers et al., Mitochondrial Replacement Therapy: The Road to 
the Clinic in Canada, J. OBSTET. GYNAECOL. CAN. 916–17 (2017).
172. Id.
173. Mullin, supra note 4.
174. Knoppers et al., supra note 171, at 117.
175. Kaiser, supra note 103.
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technology.
176
In addition to researchers going abroad, there is a substantial 
risk of “medical tourism” whereby Americans will travel to other countries, 
such as the United Kingdom, in order to have this procedure.
177
If the proce-
dure occurs in a different country than the child’s birth, the rights of the egg 
donor may be in question. If an American woman has MRT in the United 
Kingdom, and the child is born in America, the United Kingdom’s parental 
rights laws would not apply.
178
Further, medical tourism makes clinical fol-
low-ups difficult or impossible, limiting the ability of researchers and clini-
cians’ to identify and assess any long-term risks a child born from MRT 
may face.
179
F. Ethical Considerations Counsel in Favor of Allowing Parents to 
Choose Whether to Pursue MRT
Research and clinical trials of MRT can be conducted ethically, as is al-
ready happening in other countries such as the United Kingdom, as dis-
cussed above. Considerations such as the rights of the egg donor, the impact 
on the child, and the scope of the therapy are valid but ultimately counsel in 
favor of continuing to pursue MRT.
1. Rights of the Egg Donor
There are concerns about whether the egg donor would be considered a 
parent of the child,
180
what information about the egg donor should be avail-
able to the child, and what information about the child should be available 
to the donor.
181
In the United Kingdom, MRT egg donors do not have paren-
tal rights.
182
This is appropriate because the genetic contribution from the 
egg donor is only mtDNA, which is less than one tenth of one percent of the 
child’s entire DNA sequence. Concern over whether an egg donor wants pa-
rental rights are not pressing due to the small number of prospective parents 
who are candidates for MRT and the high number of people who are willing 
to donate their eggs for studies in the United Kingdom.
183
As long as the 
terms are clearly outlined and egg donors provide informed consent, any is-
sues with egg donors will be minimal.
mtDNA makes up a very small fraction of the genome in terms of 
unique DNA sequences, however, every somatic cell has thousands of cop-
176. Dohn, supra note 135, at 3.
177. See Castro, supra note 19, at 734.
178. See id.
179. Id.
180. See, e.g., id. at 728.
181. Id. at 733
182. Id. at 728.
183. Rebecca Dimond, Social and Ethical Issues in Mitochondrial Donation, 115 BRIT.
MED. BULL. 173, 179 (2015).
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ies of mtDNA and only two copies of nuclear DNA.
184
Mitochondria are 
essential to energy production in the cell and to programmed cell death.
185
This makes mtDNA very important to cellular function, which is why 
mtDNA diseases are so severe and devastating.
186
The question of how 
much DNA a child inherits from the oocyte donor is complicated and can be 
answered best if scientists are free to research the process. The role of the 
oocyte donor is complex and ambiguous given the current state of 
knowledge, but with more research it could become clearer, and policy de-
cisions would be better informed.
2. Children Born from MRT
Since germline cell therapy affects embryos, the human recipient of 
MRT cannot choose whether or not to undergo this treatment, which has led 
to ethical debates surrounding consent.
187
Since the recipient of MRT is the 
child resulting from the therapy, the individual who may benefit or harm 
from MRT is not able to make the decision of whether to have the therapy, 
as they are not yet in existence at the time the choice is made. It is possible 
that a child born from this therapy may not have made that decision if they 
had been able to choose.
188
While this is a valid concern, the people who ul-
timately make the decision of whether the child will be the recipient of 
MRT are the child’s parents. Parents are legally allowed to make medical 
decisions for children who are under eighteen, and this parental authority 
should extend to prenatal decisions as well.
189
Parents are in a difficult deci-
sion about whether to have a biological child or not in this situation.
190
Par-
ents already make decisions on which embryos to implant and dispose of 
based on preimplantation genetic diagnosis when undergoing IVF. During 
the process of IVF, before embryos are implanted, the embryologist per-
forms a genetic screening to determine which embryos are most likely to 
result in pregnancy.
191
Typically, embryos which have genetic diseases are 
not selected.
192
At this stage, parents also have the ability to choose the sex 
of their child if desired. The concerns surrounding consent of the recipient 
184. Tachibana et al., supra note 16, at 422.
185. Id.
186. See id.
187. What Are the Ethical Issues Surrounding Gene Therapy?, MEDLINEPLUS (Sept. 17, 
2020), https://medlineplus.gov/genetics/understanding/therapy/ethics.
188. See id.
189. See Marybeth Pompei & Francesco Pompei, Overcoming Bioethical, Legal, and 
Hereditary Barriers to Mitochondrial Replacement Therapy in the USA, 36 J. ASSISTED 
REPROD. & GENETICS 383, 387 (2018).
190. Id.
191. Nikhil Swaminathan, Better Baby-Making: Picking the Healthiest Embryo for IVF,
SCI. AM. (May 14, 2008), https://www.scientificamerican.com/article/better-baby-making-
pickin.
192. Id.
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embryo of MRT are similar to those posed by regular IVF. The decision-
making authority that parents have over the fetus created through MRT is 
not so dissimilar to that of the parents to an embryo created by IVF.
Some scientists and legislators have suggested that MRT should be per-
formed to produce exclusively male XY embryos in order to prevent the al-
tered mtDNA from being passed on to future generations, in case there are 
any long-term side effects that are unknown at the time of the procedure. 
This is not an acceptable course of action because it denies future female 
children equal access to a procedure that would prolong their lives and vast-
ly improve the quality of life. Allowing MRT to be performed to produce 
female XX embryos would provide a better chance that future female off-
spring benefit from MRT research. Additionally, the distinction between 
XY and XX embryos does not guarantee that XY embryos will develop into 
people who cannot pass on mtDNA to their children. Some XY embryos 
become children who are phenotypically female (46,XY females). One 
study reports that 6.4 per 100,000 live born females are 46,XY females.
193
Another source reports that one in 15,000 XY embryos results in a pheno-
typically female child.
194
According to current medical knowledge, 46,XY 
females usually have female external genitalia, a uterus, and fallopian tubes, 
but usually do not have functional ovaries and do not produce oocytes.
195
However, there have been reported cases of 46,XY females who have func-
tional ovaries and have had biological children.
196
This suggests that the rec-
ommendation to limit MRT to XY embryos does not accomplish the goal of 
eliminating the risk that a child born from MRT passes on their mtDNA to 
their offspring.
The choice should be in the hands of the parents, who already have a 
large amount of choice and control in the typical IVF process. During IVF, 
doctors often implant multiple embryos in the hopes that at least one will be 
viable. Implanting multiple embryos increases the chance of pregnancy, but 
also leaves the door open to multiple viable embryos. In this case, it is 
common to “selectively reduce” the number of embryos. When this hap-
pens, parents can choose which embryos are brought to term based on ge-
netics, including gender. It is possible that informed couples undergoing 
193. Agenthe Berglund et al., Incidence, Prevalence, Diagnostic Delay, and Clinical 
Presentation of Female 46,XY Disorders of Sex Development, J. CLINICAL ENDOCRINOLOGY 
& METABOLISM 4532, 4535 (2016).
194. Morten Busch, More Women than Expected Are Genetically Men, NOVO NORDISK 
FOUND. (Oct. 25, 2016), https://novonordiskfonden.dk/en/news/more-women-than-expected-
are-genetically-men.
195. Swyer Syndrome, MEDLINEPLUS (Aug. 18, 2020), https://medlineplus.gov/genetics
/condition/swyer-syndrome; see also Swyer Syndrome, NAT’L ORG. FOR RARE DISEASES,
https://rarediseases.org/rare-diseases/swyer-syndrome (last visited Feb. 17, 2021).
196. See Miroslav Dumic et al., Report of Fertility in a Woman with a Predominantly 
46,XY Karyotype in a Family with Multiple Disorders of Sexual Development, J. CLINICAL 
ENDOCRINOLOGY & METABOLISM 182, 182 (2008).
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MRT will make the decision to have male children because of the increased 
risk of passing on any genetic abnormalities through a female embryo. If the 
gender of a child is chosen in advance of implantation, this choice should 
belong to the parents, not the government. This type of legislation would 
also intrude on the physician-patient relationship, which many believe 
should be free of governmental interference.
197
There are many factors at 
play when deciding which embryos to implant during IVF or MRT, and the 
person in the best position to make this very personal and very difficult de-
cision is the parent, with the expertise and guidance of the medical profes-
sional providing the procedure.
198
3. Limits on MRT’s Therapeutic Scope
There are questions about what the limits on the use of MRT should be. 
In other countries, MRT has been used to treat infertility, though it may not 
be an effective infertility treatment for older mothers,
199
and it can be used to 
prevent the inheritance of deadly mitochondrial diseases. Some have argued 
that legislation should only permit MRT as a treatment for deadly mito-
chondrial diseases for which there is no effective treatment. In the early ex-
perimental stage, the study population can permissibly be limited to poten-
tial parents who are carriers of mtDNA diseases. Then, if proven to be safe 
on this population, the experimental group should be expanded for further 
tests of safety and efficacy. In other countries such as Greece and Spain, 
MRT is used to treat infertility when all other options have been exhausted. 
Women in this position, who have no other recourse but want to have a 
child, should be allowed to participate in later stage studies. If MRT can be 
proven effective for both preventing mitochondrial diseases and treating in-
fertility, the therapy should be provided to women on both groups.
Long-term follow up of any resulting children, as is required in the 
United Kingdom, should be part of the agreement for women who want to 
undergo MRT. Because MRT does not affect the woman who carries the 
embryo, but the child born from the therapy, any effects MRT may have on 
the subject cannot be known until the child is born.
200
To conclusively de-
termine the safety and efficacy of MRT, children born from MRT must be 
monitored.
197. Bratislav Stankovic, “It’s a Designer Baby!”: Opinions on Regulation of Preim-
plantation Genetic Diagnosis, 9 UCLA J.L. & TECH. 1, 5 (2005).
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199. Mazur et al., supra note 130, at e193.
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G. The Health Risks of MRT are Unproven and Can Only be 
Discovered Through Further Research
Some who oppose MRT argue against the therapy because safer alterna-
tives exist.
201
The executive director of the Center for Genetics and Society, 
Marcy Darnovsky, has said, “there is no compelling medical argument for 
heritable genome editing, and no need to subject our children to the risks it 
would entail, because we already have ways to prevent transmission of in-
heritable disease.”
202
These ways are not sufficient for a carrier woman who 
wants a biological child.
Germline cell therapy may affect the development of a fetus in unantic-
ipated ways, or it may have unknown long-term side effects.
203
Little is 
known about whether the interaction of mtDNA and nuclear DNA might 
cause adverse effects in the child.
204
Although there have been some chil-
dren born through MRT, the number is so small it is statistically insignifi-
cant. The only way to find out is to further carefully monitored testing. For a 
carrier woman who does not want to adopt or use an egg donor, her options 
are either to not have a child, to have a child who will inherit mutated 
mtDNA who may suffer and die at a young age, or to try MRT. Of these 
three options, MRT is the best chance for a healthy, genetically related 
child. Even if there may be side effects, that arguably is the best-case sce-
nario for the child.
Furthermore, research teams are refining MRT to alleviate this concern 
entirely. One team has conducted experiments using polar bodies rather than 
the mother’s oocyte as the source of the mother’s nuclear DNA, as dis-
cussed above.
205
H. MRT Provides Benefits Carriers of Mitochondrial Diseases
The benefits that MRT provides cannot be achieved by other means. If 
a woman who is a carrier for a mitochondrial disease wants to have a child 
and does not want to risk passing on mutant mtDNA, her only options are to 
use an egg donor or adopt.
201. Castro, supra note 19, at 733; see also Taylor Philippa, Three Parent Babies: Un-
ethical, Unnecessary, Unsafe, BIONEWS (Feb. 16, 2015), https://www.bionews.org.uk
/page_94923.
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1. MRT Provides Carriers with the Potential to Have a Healthy Baby to 
Whom they are Biologically Related
Currently, American women who are carriers of mtDNA diseases have 
no process by which they can have healthy babies to whom they are genet-
ically related. Adoption and egg donation are options, but this does not pro-
vide the woman the chance to have a biological child. Additionally, if the 
woman chooses to attempt a pregnancy without an egg donor, the child will 
likely have a severe disease and die at a young age. The trauma of losing a 
child has lifelong impact. CGTAC Committee Chair Jeffrey Kahn said:
Although MRT would not treat a person with a mitochondrial dis-
ease, its pursuit could satisfy prospective parents’ desire to bear ge-
netically related offspring with a significantly reduced risk of pass-
ing on mitochondrial disease. The limitations on MRT that we 
propose focus on protecting the health and well-being of children 
born as a result of the techniques.
206
One of the first women to have a baby as a result of MRT, giving an in-
terview with NPR under the pseudonym Tamara, was thrilled to have un-
dergone the process.
207
She struggled with infertility for years and went 
through many rounds of IVF without success, “I was quite sad. And at some 
moments I even lost my hope.”
208
Tamara underwent MRT at the Nadiya 
Clinic in Kiev and now has a son who is currently completely healthy.
209
Once she was finally pregnant, she said, “it was a lot of smiles. A lot of 
tears of happiness. I can’t describe it . . . It’s how happiness feels.”
210
This 
couple was able to have a biological child, which is especially important to 
many couples. Tamara says, “I’m so excited. I have a child. And he’s so 
beautiful. He smiles to me. He’s so cute. He’s so smart. He looks like my 
mom.”
211
2. MRT Has the Potential to Eradicate Heritable Mitochondrial Diseases
Inherited genetic diseases cause over 10,000 medical conditions.
212
Mu-
tations in mtDNA directly cause diseases such as Leigh syndrome,
213
and 
206. NAT’L ACADS. Report, supra note 17.
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now mtDNA mutations are being associated with cancer,
214
Alzheimer’s
disease, Huntington’s disease, and Parkinson’s disease.
215
With further re-
search and support from the scientific community, MRT has the potential to 
drastically reduce the pain and suffering that both a child with MRT and 
others face. With further research, MRT could also open the door to treat-
ment of other diseases for which there is currently no cure.
CONCLUSION
MRT is an innovative therapy that has the potential to prevent mito-
chondrial disease before it can ever cause harm to a child. This provides 
women who thought they could not have biological children an incredible 
opportunity with immense emotional value. Concerns about the safety and 
ethics of conducting this therapy are based on fear, rather than scientific ev-
idence, and should not prevent the progression of this research. Currently, 
we do not know if there are health effects on children born from MRT, 
though results in other countries suggest this therapy is safe. We cannot 
know if there are effects unless further research is conducted. MRT is no 
different from other cutting-edge therapeutic treatments because trials must 
be conducted in order to learn. The rider which bans clinical trials of MRT 
should be modified to allow the FDA to do its job and evaluate applications 
for clinical trials. The ban is not based in science, nor was the public or the 
expert scientific agency who regulates such therapy consulted in the imple-
mentation of the ban. The decision on whether to pursue MRT should be 
made on the merits of the therapy, and these merits can only be evaluated if 
the ban is lifted.
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